BIOA-B BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for intravenous treatment. Further, it is developing lecanemab for subcutaneous treatment; lecanemab, which is in Phase 3 clinical trials for presymptomatic treatment; exidavnemab, which is in Phase 2 clinical trials; lecanemab back-up, BAN2803, ND3014, and BAN2802, which are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, and PD-BT2238, which are in the research stage. The company has a research and collaboration agreement with Eli Lilly to develop a new drug candidate combining the BrainTransporter technology with a Lilly proprietary molecule, and with Mesenkia Therapeutics to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About BioArctic (STO: BIOA-B)
›
BioArctic (STO: BIOA-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 150 employees.
The shares were at 300.60 SEK on 20 November 2026, up 13.5% over 52 weeks. Its 52-week range is 261.20 SEK to 364.40 SEK: the price is 17.5% below the high and 15.1% above the low.
At a market capitalisation of 26.68B SEK, it trades at 254.7 times trailing earnings and 103.7 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 669% for BIOA-B. It pays a dividend yielding 0.65% (it pays out 174% of its earnings), against a median of 0.95% among the dividend payers in that peer group.
BioArctic reports return on equity of 52.0%, an operating margin of 19.6% and revenue down 36.9% year over year.
It holds more cash than debt, a net cash position of 1.90B SEK. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 4 analysts cover the stock; their mean price target of 314.00 SEK is 4.5% above the current price. The next earnings report is expected on 25 November 2026.